1Settimana·

ELI LILLY'S GLP-1 PILL HITS KEY MILESTONE

$LLY (+3,76%) oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Ph 3 trial

$HIMS (+4,02%)
$NOVO B (+1,31%)

9 Commenti

StockAddict@StockAddict

1Settimana

Can anyone explain this? Lilly's pills lead to a maximum weight loss of 8% - share 15% high.
Novo's pills lead to a weight loss of 20% (below expectation) - share since then -50%

•

Olli@Olli68

1Settimana

@StockAddict Novos syringes

•

SemiGrowth@SemiGrowth

1Settimana

@StockAddict the thing is that is a pill that have higher acceptance among users. 8% over 40 weeks. CagriSema has achieved 16% over 68 weeks in PH3 (Novo, injections), which is not good. The hope I see with Novo is Amycretin, also a pill, which in a phase 2a study at the highest dose lost 22% in 36 weeks (or 16% in 28 weeks with moderate dose). That is completely sick and would make the Lilly pill nonsensical.

•